Stock Analysis

Tactile Systems Technology Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

NasdaqGM:TCMD
Source: Shutterstock

Tactile Systems Technology (NASDAQ:TCMD) Third Quarter 2022 Results

Key Financial Results
  • Revenue: US$65.3m (up 24% from 3Q 2021).
  • Net loss: US$2.28m (loss narrowed by 32% from 3Q 2021).
  • US$0.11 loss per share (improved from US$0.17 loss in 3Q 2021).
earnings-and-revenue-growth
NasdaqGM:TCMD Earnings and Revenue Growth November 9th 2022

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tactile Systems Technology Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) missed analyst estimates by 29%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 16% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Tactile Systems Technology's balance sheet and an in-depth analysis of the company's financial position.

Valuation is complex, but we're here to simplify it.

Discover if Tactile Systems Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGM:TCMD

Tactile Systems Technology

A medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States.

Undervalued with reasonable growth potential.

Similar Companies

Community Narratives

Priced for AI perfection - cracks are emerging
Fair Value US$90.15|38.468999999999994% overvalued
ChadWisperer
ChadWisperer
Community Contributor
NVDA Market Outlook
Fair Value US$341.12|63.406% undervalued
NateF
NateF
Community Contributor
Karoon Energy (ASX:KAR) - Buy Baby Buy 🚀
Fair Value AU$5.91|72.843% undervalued
StockMan
StockMan
Community Contributor